The International Society for Sexual Medicine (ISSM), along with the International Society for the Study of Women’s Sexual Health (ISSWSH) and nine other medical organizations, has endorsed the “Global Consensus Position Statement on the Use of Testosterone Therapy for Women.” The position statement provides guidelines for clinicians who consider prescribing testosterone therapy to female patients. […]
Earlier this month, the U.S. Food and Drug Administration (FDA) changed the safety labeling for Addyi (flibanserin), a medication used to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Women with this type of HSDD have little or no interest in sex, even though they have had a satisfying libido in the […]
Aromatase inhibitors (AIs) are associated with hypoactive sexual desire disorder (HSDD) and fecal incontinence in breast cancer survivors ten years after diagnosis, according to a recent Journal of Sexual Medicine study.
On June 4, an advisory panel to the U.S. Food and Drug Administration (FDA) voted 18-6 in favor of recommending the approval of flibanserin for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in the United States.
Results of a recent drug trial suggest that premenopausal women with hypoactive sexual desire disorder (HSDD) may benefit from a daily dose of flibanserin, a medication designed to improve sexual desire.